High prescription drug use and associated costs among medicaid-eligible children with autism spectrum disorders identified by a population-based surveillance network

Annals of Epidemiology

Volumn 22, Issue 1, 2012, Pages 1-8

  Logan, Sarah L ^a   Nicholas, Joyce S ^a   Carpenter, Laura A ^a   King, Lydia B ^a   Garrett Mayer, Elizabeth ^a   Charles, Jane M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Autism; Medicaid; Psychotropic Medication; Public Health Surveillance

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ARIPIPRAZOLE; ATOMOXETINE; BENZATROPINE; BUSPIRONE; CARBAMAZEPINE; CHLORAL HYDRATE; CITALOPRAM; CLONIDINE; ETIRACETAM; GUANFACINE; LORAZEPAM; NEUROLEPTIC AGENT; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; RAMELTEON; RISPERIDONE; SERTRALINE;

ADOLESCENT; AGE; ARTICLE; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; AUTISM; CHILD; COST OF ILLNESS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL;

ADOLESCENT; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; FEMALE; HUMANS; MALE; MEDICAID; POPULATION SURVEILLANCE; PRESCRIPTION DRUGS; SOUTH CAROLINA; UNITED STATES;

EID: 83055180252     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2011.10.007     Document Type: Article

References (33)

1. Aman M.G., Lam K.L., Van Bourgondien M.E. Medication patterns in patients with autism: temporal, regional, and demographic influences. J Child Adolesc Psychopharmacol 2005, 15:116-126.
2. Green V.A., Pituch K.A., Itchon J., Choi A., O'Reilly M., Sigafoos J. Internet survey of treatments used by parents of children with autism. Res Dev Disabil 2006, 27:70-84.
3. Oswald D.P., Sonenklar N.A. Medication use among children with autism spectrum disorders. J Child Adolesc Psychopharmacol 2007, 17:348-355.
4. Rosenberg R., Mandell D., Farmer J., Law J., Marvin A., Law P. Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007-2008. J Autism Dev Disord 2010, 40:342-351.
5. Witwer A., Lecavalier L. Treatment incidence and patterns in children and adolescents with autism spectrum disorders. J Child Adolesc Psychopharmacol 2005, 15:671-676.
6. Mandell D.S., Cao J., Ittenbach R.F., Pinto-Martin J.A. Medicaid expenditures for children with autistic spectrum disorders: 1994 to 1999. J Autism Dev Disord 2006, 36:475-485.
7. Croen L.A., Najjar D.V., Ray T., Lotspeich L., Bernal P. A comparison of health care utilization and costs of children with and without autism spectrum disorders in a large group-model health plan. Pediatrics 2006, 118:1203-1211.
8. Mandell D.S., Morales K.H., Marcus S.C., Stahmer A.C., Doshi J., Polsky D.E. Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics 2008, 121:e441-e448.
9. Rubin D.M., Feudtner C., Localio R., Mandell D.S. State variation in psychotropic medication use by foster care children with autism spectrum disorder. Pediatrics 2009, 124:e305-e312.
10. American Academy of Pediatrics. Children with autism frequently receive psychotropic medications. Science Daily. Available at: Retrieved October 2010. http://www.sciencedaily.com/releases/2010/05/100502080228.htm.
11. Langworthy-Lam K.S., Aman M.G., Van Bourgondien M.E. Prevalence and patterns of use of psychoactive medicines in individuals with autism in the autism society of North Carolina. J Child Adolesc Psychopharmacol 2002, 12:311-321.
12. Esbensen A., Greenberg J.S., Seltzer M.M., Aman M.G. A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders. J Autism Dev Disord 2009, 39:1339-1349.
13. Martin A., Scahill L., Klin A., Volkmar F. Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use. J Am Acad Child Adolesc Psychiatry 1999, 38:923-931.
14. Mandell D.S., Novak M.M., Zubritsky C.D. Factors associated with the age of diagnosis among children with autism spectrum disorders. Pediatrics 2005, 116:1480-1486.
15. Wiggins L.D., Baio J., Rice C. Examination of the time between first evaluation and first autism spectrum diagnosis in a population-based sample. J Dev Behav Pediatr 2006, 27(suppl 2):S79-S87.
16. Prevalence of autism spectrum disorders-autism and developmental disabilities monitoring network, United States, 2006. MMWR Surveill Summ 2009, 58:1-20. Centers for Disease Control and Prevention.
17. Prevalence of autism spectrum disorders-autism and developmental disabilities monitoring network, 14 sites, United States, 2002. MMWR Surveill Summ 2007, 56(SS01):12-28. Centers for Disease Control and Prevention, ADDM Network Surveillance Year 2002 Principal Investigators.
18. Nicholas J., Charles J., Carpenter L., King L., Jenner W., Spratt E. Prevalence and characteristics of children with autism-spectrum disorders. Ann Epidemiol 2008, 18:130-136.
19. Avchen R., Wiggins L., Devine O., Van Naarden Braun K., Rice C., et al. Evaluation of a records-review surveillance system used to determine the prevalence of autism spectrum disorders. J Autism Dev Disord 2011, 41:227-236.
20. Nicholas J., Carpenter L., King L., Jenner W., Charles J. Autism spectrum disorders in preschool-aged children: Prevalence and comparison to a school-aged population. Ann Epidemiol 2009, 19:808-814.
21. Nicholas J, Carpenter L, King L, Jenner W, Wahlquist A, Logan S, et al. Completeness of case ascertainment for surveillance of autism spectrum disorders using the Autism and Developmental Disabilities Monitoring Network methodology. Paper presented at the International Meeting for Autism Research: Completeness of Case Ascertainment for Surveillance of Autism Spectrum Disorders Using the Autism Developmental Disabilities Monitoring Network Methodology, May 12, 2011, San Diego, CA. Available at: Accessed October 24, 2011. http://imfar.confex.com/imfar/2011/webprogram/Paper9298.html.
22. Diagnostic and Statistical Manual of Mental Disorder 2000, American Psychiatric Association, American Psychiatric Association, Washington, DC. 4th ed, text revision.
23. Micromedex® Healthcare Series (Internet database). Greenwood Village, CO. Thomson Healthcare. Updated periodically.
24. Arnsten A., Scahill L., Findling R. Alpha-2 adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: Emerging concepts from New Data. J Child Adolesc Psychopharmacol 2007, 393-406.
25. Posey D., Puntney J., Sasher T., Kem D., McDougle C. J Child Adolesc Psychopharmacol 2004, 14:233-241.
26. Arnsten A., Scahill L., Findling R. Alpha-2 adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: Emerging concepts from New Data. J Child Adolesc Psychopharmacol 2007, 393-406.
27. Lachenbruch P.A. Comparisons of two-part models with competitors. Stat Med 2001, l20:1215-1234.
28. Lachenbruch P.A. Analysis of data with excess zeros. Stat Methods Med Res 2002, 11:297-302.
29. Williams K., Wheeler D.M., Silove N., Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2010, 8. (CD004677).
30. Levy S.E., Hyman S.L. Complementary and alternative medicine treatments for children with autism spectrum disorders. Child Adolesc Psychiatr Clin North Am. 2008, 17:803-820.
31. Meiri G., Bichovsky Y., Belmaker R.H. Omega 3 fatty acid treatment in autism. J Child Adolesc Psychopharmacol 2009, 19:449-451.
32. dosReis S., Zito J.M., Safer D.J., Gardner J.F., Puccia K.B., Owens P.L. Multiple psychotropic medication use for youths: a two-state comparison. J Child Adolesc Psychopharmacol 2005, 15:68-77.
33. Martin A., Van Hoof T., Stubbe D., Sherwin T., Scahill L. Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid Managed Care. Psychiatr Serv 2003, 54:72-77.